Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
RENSCHLER MARKUS MD | President and CEO | Nov 20 | Option Exercise | 1.53 | 84,637 | 129,366 | 1,073,373 | Nov 22 01:48 PM | Gaiero David G | Chief Financial Officer | Nov 20 | Option Exercise | 1.68 | 73,940 | 124,433 | 88,040 | Nov 22 01:47 PM | Novo Holdings A/S | 10% Owner | Jul 20 | Sale | 2.75 | 100,000 | 275,140 | 3,522,136 | Jul 20 08:01 PM | Novo Holdings A/S | 10% Owner | Jul 19 | Sale | 2.76 | 1,900 | 5,247 | 3,622,136 | Jul 20 08:01 PM | Novo Holdings A/S | 10% Owner | Jul 18 | Sale | 2.76 | 6,500 | 17,923 | 3,624,036 | Jul 18 08:27 PM | Novo Holdings A/S | 10% Owner | Jul 17 | Sale | 2.75 | 21,100 | 58,000 | 3,630,536 | Jul 18 08:27 PM | Novo Holdings A/S | 10% Owner | Jul 14 | Sale | 2.74 | 11,000 | 30,102 | 3,651,636 | Jul 18 08:27 PM | Novo Holdings A/S | 10% Owner | Jun 30 | Sale | 2.63 | 200,937 | 529,288 | 3,662,636 | Jul 03 06:29 PM | Novo Holdings A/S | 10% Owner | Jun 27 | Sale | 1.77 | 31,978 | 56,687 | 3,863,573 | Jun 28 09:35 PM | Novo Holdings A/S | 10% Owner | Jun 26 | Sale | 1.79 | 8,437 | 15,106 | 3,895,551 | Jun 28 09:35 PM | Novo Holdings A/S | 10% Owner | Jun 23 | Sale | 1.88 | 3,423 | 6,447 | 3,903,988 | Jun 23 07:17 PM | Novo Holdings A/S | 10% Owner | Jun 22 | Sale | 1.94 | 5,041 | 9,783 | 3,907,411 | Jun 23 07:17 PM | Novo Holdings A/S | 10% Owner | Jun 21 | Sale | 1.99 | 4,834 | 9,641 | 3,912,452 | Jun 23 07:17 PM | Novo Holdings A/S | 10% Owner | Jun 20 | Sale | 2.11 | 744 | 1,573 | 3,917,286 | Jun 20 05:53 PM | Novo Holdings A/S | 10% Owner | Jun 16 | Sale | 2.03 | 5,983 | 12,142 | 3,918,030 | Jun 20 05:53 PM | Novo Holdings A/S | 10% Owner | Jun 15 | Sale | 2.03 | 10,002 | 20,304 | 3,924,013 | Jun 20 05:53 PM | Novo Holdings A/S | 10% Owner | Jun 14 | Sale | 2.11 | 2,872 | 6,050 | 3,934,015 | Jun 14 08:18 PM | Novo Holdings A/S | 10% Owner | Jun 13 | Sale | 2.10 | 2,626 | 5,515 | 3,936,887 | Jun 14 08:18 PM | Novo Holdings A/S | 10% Owner | Jun 12 | Sale | 2.06 | 900 | 1,858 | 3,939,513 | Jun 14 08:18 PM | RENSCHLER MARKUS MD | President and CEO | Dec 21 | Option Exercise | 1.07 | 136,782 | 146,060 | 978,736 | Dec 23 04:47 PM | Zakrzewski Joseph S | Director | Dec 07 | Buy | 1.30 | 21,202 | 27,563 | 154,618 | Dec 08 05:09 PM |
|